XML 51 R34.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segment Information (Tables)
 12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Summary Of Disaggregated Research And Development Expenses

In addition to the significant expense categories included within net income presented on the Company's statements of operations and comprehensive loss, see below for disaggregated research and development expenses:

 

 

 

Year Ended December 31,

 

 

 

2024

 

 

2023

 

 

2022

 

External clinical development expenses (1):

 

 

 

 

 

 

 

 

 

Darovasertib

 

$

55,335

 

 

$

25,829

 

 

$

13,433

 

IDE397(2)

 

 

16,629

 

 

 

11,985

 

 

 

9,426

 

IDE161

 

 

9,743

 

 

 

7,104

 

 

 

2,749

 

Personnel related and stock-based compensation

 

 

54,543

 

 

 

38,948

 

 

 

26,717

 

Other research and development expenses (3):

 

 

158,423

 

 

 

45,642

 

 

 

37,211

 

Total research and development expenses

 

$

294,673

 

 

$

129,508

 

 

$

89,536

 

 

(1) External clinical development expenses include manufacturing and clinical trial costs. These expenses are primarily for services provided by

external consultants, CMOs and CROs.

(2) IDE397 includes costs from the Amgen CTCSA

(3) Other research and development expenses include manufacturing and clinical trial costs for preclinical and earlier clinical stage programs.

These expenses are primarily for services provided by external consultants, CMOs and CROs.